January 17, 2011Open Access

Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study provides Class III evidence that pegylated interferon-α-2b in patients with unresectable, progressive, symptomatic, or life-threatening PNs results in radiographic reduction or stabilization of PN size.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Jakacki et al. (Mon,) studied this question.

synapsesocial.com/papers/69dc1ebe796be608a2b6506a https://doi.org/https://doi.org/10.1212/wnl.0b013e318207b031

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas2009 · 78 citations
2Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups2004 · 41 citations
3The therapeutic value of poly(ethylene glycol)-modified proteins1991 · 278 citations
4The role of interferon alfa in the treatment of metastatic melanoma.1997 · 57 citations
5Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 12003 · 86 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo